Report cover image

Biopharma Cold Chain Logistics Market Share, Size, Trends, Industry Analysis Report, By Component (Storage [Warehouse, Refrigerated Container], Transportation [Sea Freight Logistics, Air Freight Logistics, Overland Logistics], Monitoring Components); By R

Publisher Polaris Market Research & Consulting LLP
Published Sep 01, 2025
Length 118 Pages
SKU # PLRS20470272

Description

The global biopharma cold chain logistics market size is expected to reach USD 51.58 Billion by 2034 according to a new study by Polaris Market Research. The Report “Biopharma Cold Chain Logistics Market Share, Size, Trends, Industry Analysis Report, By Component (Storage, Transportation, and Monitoring Components, and Software); By Regions -Market Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global market is anticipated to grow owing to the necessity of cold chain infrastructure in the supply chain network for the temperature sensitive vaccines and drugs, cost containment measures, and technology enabled services for real time monitoring. Moreover, government’s positive initiatives to reduce the wastage and enhancement of services at the local level is also expected to boost the investments in the concerned market.

The market is fragmented based on type, component, and region. In terms of type, the market is segmented into cold and non-cold. Based on component, the biopharma cold chain logistics market is bifurcated as storage, transportation, and monitoring components. Storage segment is further segmented as warehouse, and refrigerated container. Transportation is further segregated as sea freight logistics, air freight logistics, and overland logistics. Monitoring components is bifurcated as hardware and software.

Segment Highlight

The storage segment accounted for the largest revenue share in 2024 and is expected to continue its dominance over the forecast period on account of the growing demand for temperature-sensitive pharmaceuticals.

Monitoring components segment is expected to witness significant growth over the projected period on account of the increasing need to maintain safety and integrity of the biopharmaceuticals

North America accounted for the largest revenue share in 2024 owing to the growing demand for biopharma cold chain logistics and presence of several market players operating in the U.S. and Canada

List of Key Players

Air Canada

DB Schenker

Kuehne+ Nagel

United Parcel Service of America, Inc.

Deutsche Post AG

Polaris Market Research has segmented the biopharma cold chain logistics market report on the basis of component and region

Biopharma Cold Chain Logistics, Component Outlook (Revenue - USD Billion, 2020 – 2034)

Storage

Warehouse

Refrigerated Container

Transportation

Sea Freight Logistics

Air Freight Logistics

Overland Logistics

Monitoring Components

Hardware

Sensors

RFID Devices

Telematics

Networking Devices

Software

Biopharma Cold Chain Logistics, Regional Outlook (Revenue - USD Billion, 2020 – 2034)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

118 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. U.S. Cell Culture Media & Cell Lines Market Insights
4.1. ATP Assays Market – Market Snapshot
4.2. ATP Assays Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing Demand for Biopharmaceutical Production
4.2.1.2. Advancements in Regenerative Medicine
4.2.2. Restraints and Challenges
4.2.2.1. High Cost and Specialized Expertise
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. ATP Assays Market End Use Trends
4.6. Value Chain Analysis
5. U.S. Cell Culture Media & Cell Lines Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Cell Culture Media & Cell Lines Market, by Product, 2020-2034 (USD Billion)
5.3. Traditional Cell Lines
5.3.1. U.S. Cell Culture Media & Cell Lines Market, by Traditional Cell Lines, by Region, 2020-2034 (USD Billion)
5.4. Classical Media
5.4.1. U.S. Cell Culture Media & Cell Lines Market, by Classical Media, by Region, 2020-2034 (USD Billion)
5.5. Stem Cells & Blood-derived Cells
5.5.1. U.S. Cell Culture Media & Cell Lines Market, by Stem Cells & Blood-derived Cells, by Region, 2020-2034 (USD Billion)
5.6. Specialty Media
5.6.1. U.S. Cell Culture Media & Cell Lines Market, by Specialty Media, by Region, 2020-2034 (USD Billion)
6. U.S. Cell Culture Media & Cell Lines Market, by Application
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Cell Culture Media & Cell Lines Market, by Application, 2020-2034 (USD Billion)
6.3. Biopharmaceutical Production
6.3.1. U.S. Cell Culture Media & Cell Lines Market, by Biopharmaceutical Production, by Region, 2020-2034 (USD Billion)
6.4. Diagnostics
6.4.1. U.S. Cell Culture Media & Cell Lines Market, by Diagnostics, by Region, 2020-2034 (USD Billion)
6.5. Drug Screening and Development
6.5.1. U.S. Cell Culture Media & Cell Lines Market, by Drug Screening and Development, by Region, 2020-2034 (USD Billion)
6.6. Tissue Engineering and Regenerative Medicine
6.6.1. U.S. Cell Culture Media & Cell Lines Market, by Tissue Engineering and Regenerative Medicine, by Region, 2020-2034 (USD Billion)
6.7. Others
6.7.1. U.S. Cell Culture Media & Cell Lines Market, by Others, by Region, 2020-2034 (USD Billion)
7. U.S. Cell Culture Media & Cell Lines Market, by End Use
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Cell Culture Media & Cell Lines Market, by End Use, 2020-2034 (USD Billion)
7.3. Large Biopharmaceutical Companies
7.3.1. U.S. Cell Culture Media & Cell Lines Market, by Large Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)
7.4. Small and Mid-sized Biotechnology Companies
7.4.1. U.S. Cell Culture Media & Cell Lines Market, by Small and Mid-sized Biotechnology Companies, by Region, 2020-2034 (USD Billion)
7.5. Contract Research and Manufacturing Organizations (CROs/CMOs
7.5.1. U.S. Cell Culture Media & Cell Lines Market, by Contract Research and Manufacturing Organizations (CROs/CMOs, by Region, 2020-2034 (USD Billion)
7.6. Research and Academic Institutes
7.6.1. U.S. Cell Culture Media & Cell Lines Market, by Research and Academic Institutes, by Region, 2020-2034 (USD Billion)
7.7. Hospitals and Diagnostic Laboratories
7.7.1. U.S. Cell Culture Media & Cell Lines Market, by Hospitals and Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
7.8. Others
7.8.1. U.S. Cell Culture Media & Cell Lines Market, by Others, by Region, 2020-2034 (USD Billion)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. AllCells
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. ATCC
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Danaher
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. FUJIFILM Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Lonza
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Merck KGaA
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. Nucleus Biologics
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. PromoCell GmbH
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. Sartorius AG
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. STEMCELL Technologies
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development
9.11. Thermo Fisher Scientific
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us